Table 1. Patient characteristics.
| Characteristic | No. of Patients (%) (n = 140) |
|---|---|
| Sex | |
| Male | 75 (54) |
| Female | 65 (46) |
| Age, years | |
| Median | 70 |
| Range | 40-87 |
| Race | |
| White | 134 (96) |
| Other | 6 (4) |
| Chronic respiratory disease | |
| Yes | 51 (36) |
| No | 89 (64) |
| Disease stage | |
| I | 16 (11) |
| II | 15 (11) |
| III | 106 (76) |
| IV | 3 (2) |
| Histology | |
| Squamous cell Adenocarcinoma | 60 (43) |
| NSCLC, NOS | 46 (33) |
| 34 (24) | |
| Karnofsky performance status score | |
| 90-100 | 49 (35) |
| 80 | 69 (49) |
| <80 | 22 (16) |
| Smoking status | |
| Current | 26 (19) |
| Former | 106 (76) |
| Never | 8 (6) |
| Treatment | |
| Concurrent chemoradiation | 64 (46) |
| Chemotherapy+concurrent chemoradiation | 47 (34) |
| Radiation therapy | 18 (13) |
| Sequencial chemoradiation therapy | 11 (8) |
| Radiation total dose, Gy (GyE for protons) | |
| Median | 69.6 |
| Range | 60-87.5 |
| Radiation technique | |
| 3D-CRT | 44 (31) |
| IMRT | 64 (46) |
| PBT | 32 (23) |
| Radiotherapy fractionation | |
| Once a day | 117 (84) |
| Twice a day | 23 (16) |
| Mean lung dose, Gy (GyE for protons) (n=132) | |
| Median | 17 |
| Range | 3-67 |
| V20, %(n=132) | |
| Median | 30 |
| Range | 4-44 |
| Baseline DLCO (percentage of predicted), % | |
| Median | 68 |
| Range | 26-126 |
| Baseline FEV1 (percentage of predicted), % | |
| Median | 67 |
| Range | 20-115 |
Abbreviations: NSCLC, NOS, non–small-cell lung cancer, not otherwise specified; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; PBT, proton beam radiation therapy; GyE, cobalt-Gray equivalent; V20, volume of normal lung receiving ≥20 Gy; DLCO, capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second.